Plus Therapeutics develops precision diagnostics and targeted radiopharmaceuticals for central nervous system cancers. The company operates CNSide Diagnostics, which offers laboratory-developed tests to identify tumor cells that have metastasized to the brain and cerebrospinal fluid, generating revenue through commercial payor agreements. Its lead clinical-stage product is a novel injectable radiotherapy using rhenium-186 designed for direct delivery to CNS tumors including glioblastoma and leptomeningeal metastases, alongside a secondary candidate targeting solid organ cancers, with both therapies designed to deliver concentrated radiation doses directly to tumors while minimizing exposure to healthy tissue.